Loading…
Loading…
2630.HK (Vigonvita Life Sciences Co., Ltd.) is a recent IPO.
It began trading on November 6, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
2630.HK does not currently pay a dividend.
See exactly how 2630.HK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 2630.HK and 80,000+ other tickers.
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RNA-dependent RNA polymerase inhibitor…
No recent news available.